safinamide and Aura
safinamide has been researched along with Aura in 5 studies
Research
Studies (5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fariello, RG | 1 |
| Chazot, PL | 2 |
| Fariello, RG; Maj, R; McArthur, RA; Pevarello, P; Salvati, P; Ukmar, G; Varasi, M | 1 |
Reviews
4 review(s) available for safinamide and Aura
| Article | Year |
|---|---|
Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epilepsy; Humans; Parkinson Disease | 2004 |
Safinamide.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Clinical Trials as Topic; Epilepsy; Humans; Parkinson Disease | 2007 |
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Epilepsy; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Restless Legs Syndrome | 2007 |
Safinamide (Newron Pharmaceuticals).
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Contraindications; Epilepsy; Humans; Parkinson Disease; Structure-Activity Relationship | 2001 |
Other Studies
1 other study(ies) available for safinamide and Aura
| Article | Year |
|---|---|
PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Diazepam; Epilepsy; Hippocampus; Kainic Acid; Lamotrigine; Male; Neuroprotective Agents; Rats; Rats, Wistar; Triazines | 1998 |